News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,859 Results
Type
Article (44251)
Company Profile (313)
Press Release (706275)
Multimedia
Podcasts (129)
Webinars (22)
Section
Business (211166)
Career Advice (2116)
Deals (36814)
Drug Delivery (141)
Drug Development (83552)
Employer Resources (176)
FDA (16922)
Job Trends (15537)
News (357797)
Policy (34151)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2640)
Accelerated approval (47)
Adcomms (28)
Allergies (177)
Alliances (51589)
ALS (214)
Alzheimer's disease (1816)
Antibody-drug conjugate (ADC) (456)
Approvals (17297)
Artificial intelligence (686)
Autoimmune disease (293)
Automation (57)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (226)
Biotechnology (188)
Bladder cancer (187)
Brain cancer (75)
Breast cancer (757)
Cancer (5871)
Cardiovascular disease (483)
Career advice (1802)
Career pathing (43)
CAR-T (335)
CDC (59)
Celiac Disease (3)
Cell therapy (912)
Cervical cancer (47)
Clinical research (72385)
Collaboration (2111)
Company closure (5)
Compensation (1397)
Complete response letters (87)
COVID-19 (2815)
CRISPR (113)
C-suite (1146)
Cystic fibrosis (157)
Data (7887)
Decentralized trials (3)
Denatured (38)
Depression (165)
Dermatology (86)
Diabetes (593)
Diagnostics (7015)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (327)
Drug pricing (219)
Drug shortages (34)
Duchenne muscular dystrophy (287)
Earnings (93806)
Editorial (69)
Employer branding (21)
Employer resources (155)
Events (122434)
Executive appointments (1108)
FDA (20674)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1735)
Gene editing (240)
Generative AI (59)
Gene therapy (741)
GLP-1 (1103)
Government (4874)
Grass and pollen (7)
Guidances (409)
Healthcare (19181)
HIV (79)
Huntington's disease (57)
IgA nephropathy (99)
Immunology and inflammation (301)
Immuno-oncology (94)
Indications (192)
Infectious disease (3153)
Inflammatory bowel disease (224)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (293)
Interviews (330)
IPO (16945)
IRA (57)
Job creations (4074)
Job search strategy (1500)
JPM (65)
Kidney cancer (19)
Labor market (99)
Layoffs (591)
Leadership (41)
Legal (8427)
Liver cancer (100)
Longevity (33)
Lung cancer (768)
Lymphoma (432)
Machine learning (62)
Management (60)
Manufacturing (1075)
MASH (192)
Medical device (14013)
Medtech (14134)
Mergers & acquisitions (21111)
Metabolic disorders (1535)
mRNA (216)
Multiple sclerosis (187)
NASH (18)
Neurodegenerative disease (419)
Neuropsychiatric disorders (109)
Neuroscience (3348)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4578)
Now hiring (78)
Obesity (723)
Opinion (312)
Ovarian cancer (220)
Pain (270)
Pancreatic cancer (301)
Parkinson's disease (360)
Partnered (34)
Patents (601)
Patient recruitment (673)
Peanut (65)
People (61612)
Pharmaceutical (85)
Pharmacy benefit managers (34)
Phase 1 (22468)
Phase 2 (31858)
Phase 3 (23842)
Pipeline (8742)
Policy (332)
Postmarket research (2659)
Preclinical (9595)
Press Release (68)
Prostate cancer (300)
Psychedelics (57)
Radiopharmaceuticals (328)
Rare diseases (1108)
Real estate (6320)
Recruiting (72)
Regulatory (26290)
Reports (57)
Research institute (2463)
Resumes & cover letters (362)
Rett syndrome (39)
RNA editing (23)
RSV (88)
Schizophrenia (185)
Series A (294)
Series B (215)
Service/supplier (11)
Sickle cell disease (115)
Special edition (26)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3790)
State (2)
Stomach cancer (19)
Supply chain (128)
Tariffs (99)
The Weekly (88)
Vaccines (1119)
Venture capital (109)
Weight loss (476)
Women's health (126)
Worklife (20)
Date
Today (270)
Last 7 days (980)
Last 30 days (3693)
Last 365 days (30777)
2026 (12544)
2025 (30677)
2024 (35760)
2023 (40626)
2022 (51797)
2021 (56326)
2020 (54789)
2019 (47398)
2018 (35767)
2017 (33135)
2016 (32662)
2015 (38614)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (806)
Alabama (93)
Alaska (7)
Arizona (355)
Arkansas (16)
Asia (42601)
Australia (6840)
California (13317)
Canada (3784)
China (1375)
Colorado (569)
Connecticut (577)
Delaware (407)
Europe (91721)
Florida (1989)
Georgia (424)
Hawaii (3)
Idaho (62)
Illinois (1070)
India (93)
Indiana (608)
Iowa (23)
Japan (548)
Kansas (132)
Kentucky (50)
Louisiana (42)
Maine (76)
Maryland (1595)
Massachusetts (9538)
Michigan (365)
Minnesota (721)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3499)
New Mexico (30)
New York (3483)
North Carolina (1705)
North Dakota (9)
Northern California (6666)
Ohio (398)
Oklahoma (24)
Oregon (46)
Pennsylvania (2681)
Puerto Rico (29)
Rhode Island (50)
South America (1179)
South Carolina (86)
South Dakota (2)
Southern California (5252)
Tennessee (210)
Texas (2114)
United States (47063)
Utah (396)
Vermont (1)
Virginia (338)
Washington D.C. (80)
Washington State (1066)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
750,859 Results for "rigel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Lilly exits Rigel alliance, adding to RIPK1 scrap heap
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous system indications.
April 22, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
·
7 min read
Press Releases
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 14, 2026
·
1 min read
Press Releases
Rigel Reports First Quarter 2026 Financial Results
May 6, 2026
·
16 min read
Press Releases
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026
·
1 min read
Press Releases
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 12, 2026
·
13 min read
Press Releases
Rigel Appoints Michael P. Miller to the Board of Directors
February 3, 2026
·
2 min read
Press Releases
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
March 31, 2026
·
12 min read
Press Releases
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
·
19 min read
Press Releases
Rigel Provides Business Update and 2026 Outlook
January 12, 2026
·
16 min read
1 of 75,086
Next
